Physician profile
Zahid Ali
NPI 1437110673
$5,224.21
in general payments reported to CMS, 2019-2025
23 companies · $370 in 2025
The $370 reported for 2025 was more than what 91% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $1,094 · 2021: $1,302 · 2022: $935 · 2023: $569 · 2024: $201 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,755.64 | 2019-2025 | Merlin@Home, Accent, Aveir |
| Janssen Pharmaceuticals, INC | $998.04 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $441.25 | 2019-2025 | |
| Amgen INC. | $381.62 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.07 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $268.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.99 | 2021-2023 | Verquvo |
| Pfizer INC. | $193.81 | 2019-2025 | |
| Esperion Therapeutics, INC. | $118.41 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $113.20 | 2020-2021 | |
| Edwards Lifesciences Corporation | $69.20 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $51.39 | 2023-2024 | Watchman Flx, Bodyguardian |
| Sanofi-Aventis U.S. LLC | $41.37 | 2021-2022 | |
| Gilead Sciences, INC. | $36.92 | 2019 | |
| Corvista Health, INC. | $32.30 | 2025 | Corvista System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.48 | 2021-2024 | Lifevest |
| Daiichi Sankyo INC. | $25.04 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $17.27 | 2022 | |
| Scpharmaceuticals INC. | $16.44 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $15.64 | 2021 | |
| G Medical Diagnostic Services, INC. | $15.26 | 2022 | |
| Baxter Healthcare | $15.19 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $13.30 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahid Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.